What cardiologists should know about essential thrombocythemia and acute myocardial infarction: report of two cases and advanced heart failure therapies considerations

References

• Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol. 2011;29(5):573–582. doi:10.1200/JCO.2010.29.871121220604
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. 2014;28:1472–1477. doi:10.1038/leu.2014.324402162
   PubMed Web of Science ®Google Scholar
• Wolanskyj AP, Lasho TL, Schwager SM, et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol. 2005;131(2):208–213. doi:10.1111/j.1365-2141.2005.05764.x16197451
   PubMed Web of Science ®Google Scholar
• Vianello F, Cella G, Osto E, et al. Coronary microvascular dysfunction due to essential thrombocythemia and policythemia vera: the missing piece in the puzzle of their increased cardiovascular risk? Am J Hematol. 2015;90:109–113. doi:10.1002/ajh.2388125352381
   PubMed Web of Science ®Google Scholar
• Rossi C, Randi ML, Zerbinati P, Rinaldi V, Girolami A. Acute coronary disease in essential thrombocythemia and polycythemia vera. J Intern Med. 1998;244:49–53.9698024
   PubMed Web of Science ®Google Scholar
• Carobbio A, Thiele J, Passamonti F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011;117:5857–5859. doi:10.1182/blood-2011-02-33900221490340
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–2405. doi:10.1182/blood-2016-03-64354427069254
   PubMed Web of Science ®Google Scholar
• Derks A, Bloemer MH. Essential thrombocythaemia as cause of myocardial infarction. Neth Heart J. 2001;9:383–385.25696769
   PubMedGoogle Scholar
• Gangadharan V, Ticku J, Kasi V. Acute myocardial infarction in a 21-year-old male due to essential thrombocytosis. Cath Lab Digest. 2014;22(3).
   Google Scholar
• Pande S, Joshi R, Pande R. Essential thrombocythemia in a young man treated for myocardial infarction. BMJ Case Rep. 2010;2010:bcr0920092234.
   Google Scholar
• Bildirici U, Celikyurt U, Ural E. Essential thrombocythemia: a case of acute ST-segment elevation myocardial infarction in a young female. Clin Cardiol. 2009;32:104–105. doi:10.1002/clc.2042619215011
   PubMed Web of Science ®Google Scholar
• Daya SK, Gowda RM, Landis WA, Khan IA. Essential thrombocythemia-related acute ST-segment elevation myocardial infarction. A case report and literature review. Angiology. 2004;55:319–323. doi:10.1177/00033197040550031215156266
   PubMed Web of Science ®Google Scholar
• Nanavati A, Patel N, Burke J. Thrombocytosis and coronary occlusion. JACC Cardiovasc Interv. 2012;5:e18–9. doi:10.1016/j.jcin.2011.12.01822721672
   PubMed Web of Science ®Google Scholar
• Rumi E, Cazzola M. How I treat essential thrombocythemia. Blood. 2016;128:2403–2414. doi:10.1182/blood-2016-05-64334627561316
   PubMed Web of Science ®Google Scholar
• Castelli R, Gallipoli P, Schiavon R, Teatini T, Deliliers GL, Bergamaschini L. Heparin-induced thrombocytopenia in essential thrombocytosis. J Stroke Cerebrovasc Dis. 2012;21(8):916.e1–e5.
   Web of Science ®Google Scholar
• Risch L, Pihan H, Zeller C, Huber AR. ET gets HIT–thrombocytotic heparin-induced thrombocytopenia (HIT) in a patient with essential thrombocythemia (ET). Blood Coagul Fibrinolysis. 2000;11(7):663–667.11085287
   PubMed Web of Science ®Google Scholar
• Castelli R, Gallipoli P, Schiavon R, Teatini T, Deliliers GL, Bergamaschini L. Increased risk of heparin induced thrombocytopenia and thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation. J Thromb Thrombolysis. 2019;47(1):155–156. doi:10.1007/s11239-018-1773-430478722
   PubMed Web of Science ®Google Scholar
• Richard S, Perrin J, Lavandier K, Lacour JC, Ducrocq X. Cerebral venous thrombosis due to essential thrombocythemia and worsened by heparin-induced thrombocytopenia and thrombosis. Platelets. 2011;22(2):157–159. doi:10.3109/09537104.2010.52739921142409
   PubMed Web of Science ®Google Scholar
• Houston DS. Heparin-induced thrombocytopenia without thrombocytopenia in a patient with essential thrombocythemia. Am J Hematol. 2000;65(4):331–332.11074573
   PubMed Web of Science ®Google Scholar
• Reikvam H, Tiu RV. Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera. Leukemia. 2012;26:563–571. doi:10.1038/leu.2011.31422076463
   PubMed Web of Science ®Google Scholar
• Spectre G, Kalish Y, Schliamser L, Varon D. Heparin-induced thrombocytopenia in myeloproliferative disorders: a rare or under-diagnosed complication? Am J Hematol. 2008;83(5):420–423. doi:10.1002/ajh.2112818181201
   PubMed Web of Science ®Google Scholar
• Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117(10):755–761. doi:10.1016/j.amjmed.2004.06.03215541325
   PubMed Web of Science ®Google Scholar
• Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc. 2006;81(2):159–166. doi:10.4065/81.2.15916471068
   PubMed Web of Science ®Google Scholar
• Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124(16):2507–2513. doi:10.1182/blood-2014-05-57913625037629
   PubMed Web of Science ®Google Scholar
• Passamonti F, Thiele J, Girodon F, et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on myelofibrosis research and treatment. Blood. 2012;120(6):1197–1201. doi:10.1182/blood-2012-01-40327922740446
   PubMed Web of Science ®Google Scholar
• Chim CS, Kwong YL, Lie AK, et al. Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia. Arch Intern Med. 2005;165(22):2651–2658. doi:10.1001/archinte.165.22.265116344424
   PubMedGoogle Scholar
• Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29(23):3179–3184. doi:10.1200/JCO.2010.34.529821747083
   PubMed Web of Science ®Google Scholar
• Haddad M, Veinot JP, Masters RG, Hendry PJ. Essential thrombocytosis causing a massive myocardial infarction. Cardiovasc Pathol. 2003;12:216–218.12826291
   PubMed Web of Science ®Google Scholar
• Barbui T, Finazzi G, Carobbio A, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120(26):5128–33; quiz 5252. doi:10.1182/blood-2012-07-444067
   Web of Science ®Google Scholar
• Slaughter MS, Pagani FD, Rogers JG, et al. Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. J Heart Lung Transplant. 2010;29(4 Suppl):S1–S39. doi:10.1016/j.healun.2010.01.01120181499
   PubMed Web of Science ®Google Scholar
• Barbui T, Vannucchi AM, Buxhofer-Ausch V, et al. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J. 2015;5:e369. doi:10.1038/bcj.2015.9426617062
   PubMed Web of Science ®Google Scholar
• Dillinger JG, Sideris G, Henry P, Bal Dit Sollier C, Ronez E, Drouet L. Twice daily aspirin to improve biological aspirin efficacy in patients with essential thrombocythemia. Thromb Res. 2012;129(1):91–94. doi:10.1016/j.thromres.2011.09.01722014557
   PubMed Web of Science ®Google Scholar
• Mehra MR, Canter CE, Hannan MM, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update. J Heart Lung Transplant. 2016;35(1):1–23. doi:10.1016/j.healun.2015.10.02326776864
   PubMed Web of Science ®Google Scholar